T1	p 93 132	advanced epithelial ovarian carcinoma .
T2	p 296 394	patients with advanced epithelial ovarian cancer who had failed one prior platinum-based regimen .
T3	p 416 464	Patients with bidimensionally measurable disease
T4	p 980 1033	A total of 226 patients were evaluable for response .
T5	p 1901 1960	patients receiving topotecan at relapse of ovarian cancer .
T6	i 79 89	paclitaxel
T7	i 282 292	paclitaxel
T8	i 532 542	paclitaxel
T9	i 1279 1289	paclitaxel
T10	i 1509 1519	paclitaxel
T11	i 1676 1686	paclitaxel
T12	o 737 792	Cancer Quality of Life ( EORTC QOL ) -C30 questionnaire
T13	o 870 971	pain , anorexia , diarrhoea , fatigue , nausea and vomiting , dyspnea , constipation and insomnia ) .
T14	o 1180 1206	median time to progression
T15	o 1707 1775	non-cumulative haematological toxicity . Non-haematological toxicity